Table 2.

Baseline patient and disease characteristics

CharacteristicAntihypertensive agent(s) usersAntihypertensive agent(s) nonuserTotal cohort
ASI usersOthera
n (%)n = 1,487n = 783n = 2,466n = 4,736
Age at initiation of therapy
 <65 y871 (58.6%)447 (57.1%)1,940 (78.7%)3,258 (68.8%)
 ≥65 y616 (41.4%)336 (42.9%)526 (21.3%)1,478 (31.2%)
Sex
 Male1,025 (68.9%)523 (66.8%)1,815 (73.6%)3,258 (68.8%)
 Female462 (31.1%)260 (33.2%)651 (26.4%)1,478 (31.2%)
Race
 Caucasian1,192 (80.2%)583 (74.5%)1,889 (76.6%)3,664 (77.4%)
 Other295 (19.2%)200 (25.5%)577 (23.4%)1,072 (22.6%)
ECOG performance status
 0891 (59.9%)384 (49.0%)1,220 (49.5%)2,495 (52.7%)
 1574 (38.6%)386 (49.3%)1,198 (48.6%)2,158 (45.6%)
 216 (1.1%)8 (1.0%)36 (1.5%)60 (1.3%)
 Unknown6 (0.4%)5 (0.6%)12 (0.5%)23 (0.5%)
Pathology
 Clear cell1,356 (91.2%)702 (89.7%)2,177 (88.3%)4,235 (89.4%)
 Nonclear cell95 (6.4%)55 (7.0%)187 (7.6%)337 (7.1%)
 Unknown36 (2.4%)26 (3.3%)102 (4.1%)164 (3.5%)
Baseline metastatic site
 Lung1,145 (77.0%)597 (76.2%)1,887 (76.5%)3,629 (76.6%)
 Bone363 (24.4%)206 (26.3%)732 (29.7%)1,301 (27.5%)
 Liver350 (23.5%)210 (26.8%)678 (27.5%)1,238 (26.1%)
Previous nephrectomy
 Yes1,096 (73.7%)581 (74.2%)1,648 (66.8%)3,325 (70.2%)
 No351 (23.6%)168 (21.5%)688 (27.9%)1,207 (25.5%)
 Unknown40 (2.7%)34 (4.3%)130 (5.3%)204 (4.3%)
Prior type of therapy
 Any prior therapy529 (35.6%)274 (35.0%)770 (31.2%)1,573 (33.2%)
 Cytokine therapy200 (13.4%)111 (14.2%)360 (14.6%)671 (14.2%)
 Targeted therapy220 (14.8%)124 (15.8%)229 (9.3%)573 (21.1%)
Medical conditions
 Hypertension1,250 (84.1%)634 (81.0%)383 (15.5%)2,267 (47.9%)
 Diabetes mellitus347 (23.3%)116 (14.8%)197 (8.0%)660 (13.9%)

Abbreviation: ECOG, Eastern Cooperative Oncology Group.

  • aOther antihypertensive agents include B-blockers, calcium-channel blockers, diuretics, and other agents.